Abstract P2-13-04: Superior efficacy of anastrozole to tamoxifen as adjuvant therapy for postmenopausal patients with hormone-responsive breast cancer. Efficacy results of long-term follow-up data from N-SAS BC 03 trial

2012 ◽  
Author(s):  
S Imoto ◽  
S Osumi ◽  
K Aogi ◽  
Y Hozumi ◽  
H Mukai ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Therapy ◽  
Superior Efficacy ◽  
Long Term Follow Up

48. Long-term follow-up of neo-adjuvant therapy in operable breast cancer — an update of the original Edinburgh series

The Breast ◽  
1995 ◽  
Vol 4 (3) ◽  
pp. 240-241 ◽  
Author(s):  
D.A. Cameron ◽  
E.D. Anderson ◽  
P. Levack ◽  
A.P.M. Forrest ◽  
R.C.F. Leonard ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Therapy ◽  
Operable Breast Cancer ◽  
Long Term Follow Up

Importance of Long-Term Follow-Up of Women Receiving Adjuvant Therapy for Breast Cancer in the Community

2011 ◽  
Vol 29 (25) ◽  
pp. 3492-3492 ◽  
Author(s):  
Colin McCowan ◽  
John A. Dewar ◽  
Alastair M. Thompson
Keyword(s):  
Breast Cancer ◽  
Adjuvant Therapy ◽  
Long Term Follow Up

Fatigue in patients with adjuvant radiation therapy for breast cancer: long-term follow-up

2004 ◽  
Vol 130 (6) ◽  
pp. 327-333 ◽  
Author(s):  
Hans Geinitz ◽  
Frank B. Zimmermann ◽  
Reinhard Thamm ◽  
Monika Keller ◽  
Raymonde Busch ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Radiation Therapy ◽  
Adjuvant Radiation ◽  
Adjuvant Radiation Therapy ◽  
Long Term Follow Up

A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma.

1991 ◽  
Vol 9 (5) ◽  
pp. 736-740 ◽  
Author(s):  
L E Spitler
Keyword(s):  
Malignant Melanoma ◽  
Adjuvant Therapy ◽  
Randomized Trial ◽  
Control Groups ◽  
Disease Free Interval ◽  
Significant Difference ◽  
Long Term Follow Up ◽  
And Control

We conducted a long-term follow-up (median, 10.5 years) of patients included in a randomized trial of levamisole versus placebo as surgical adjuvant therapy in 203 patients with malignant melanoma. Of the patients randomized, 104 received levamisole, and 99 received placebo. The results show that there is no difference between the treatment and control groups with regard to any of the three end points analyzed. These included disease-free interval, time to appearance of visceral metastasis, and survival. Moreover, there was no significant difference between the treatment and control groups after adjusting for age, sex, or stage of disease.

Sign in / Sign up

Export Citation Format

Share Document